Literature DB >> 23175777

Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat.

Hua Zhang1, Yuanwu Liu, Li Wang, Zhen Li, Hongwen Zhang, Jihua Wu, Nafis Rahman, Yangdong Guo, Defa Li, Ning Li, Ilpo Huhtaniemi, Suk Ying Tsang, George F Gao, Xiangdong Li.   

Abstract

It is important to clarify the distinct contributions of estrogen/estrogen receptor (ER) and androgen/androgen receptor (AR) signaling and their reciprocal effects on the regulation of hepatic lipid homeostasis. We studied the molecular mechanisms underlying the preventive effects of estradiol (E2), dihydrotestosterone (DHT), or E2+DHT on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in an orchidectomized Sprague-Dawley (SD) rat model. E2 is shown to be associated with decreased fatty acid synthesis in hepatic zone 3-specific manner by increasing the phosphorylation of acetyl coenzyme-A carboxylase via an ERα-mediated pathway. DHT is shown to be associated with decreased lipid accumulation and cholesterol synthesis in a hepatic zone 1-specific manner by increasing expression of carnitine palmitotyltransferase1 and phosphorylation of 3-hydroxy-3-methyl-glutaryl-CoA reductase via an AR-mediated pathway. E2+DHT showed an additive positive effect and normalized all three impaired zones of the liver. Gene expression changes in human severe liver steatosis were similar to those of experimental rat NAFLD. Steroids reversed the histopathological NAFLD changes, likely by decreasing fatty acid and cholesterol synthesis and increasing β-oxidation. The diverse steroid effects (ER/AR) on NAFLD prevention in male rats indicate the potential applicability of ER/AR modulators for NAFLD treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175777      PMCID: PMC3588864          DOI: 10.1194/jlr.M028969

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

Review 1.  The aging male: testosterone deficiency and testosterone replacement. An up-date.

Authors:  Peter Alexandersen; Claus Christiansen
Journal:  Atherosclerosis       Date:  2004-04       Impact factor: 5.162

2.  Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

Authors:  Jessica L Yecies; Hui H Zhang; Suchithra Menon; Sihao Liu; Derek Yecies; Alex I Lipovsky; Cem Gorgun; David J Kwiatkowski; Gökhan S Hotamisligil; Chih-Hao Lee; Brendan D Manning
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

3.  Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene.

Authors:  C Lemieux; D Phaneuf; F Labrie; V Giguère; D Richard; Y Deshaies
Journal:  Int J Obes (Lond)       Date:  2005-10       Impact factor: 5.095

Review 4.  Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models.

Authors:  K A Walters; U Simanainen; D J Handelsman
Journal:  Hum Reprod Update       Date:  2010-03-15       Impact factor: 15.610

5.  A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.

Authors:  L P Ly; M Jimenez; T N Zhuang; D S Celermajer; A J Conway; D J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice.

Authors:  Sofia Movérare-Skrtic; Katrien Venken; Niklas Andersson; Marie K Lindberg; Johan Svensson; Charlotte Swanson; Dirk Vanderschueren; Jan Oscarsson; Jan-Ake Gustafsson; Claes Ohlsson
Journal:  Obesity (Silver Spring)       Date:  2006-04       Impact factor: 5.002

7.  Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.

Authors:  Y Murata; Y Ogawa; T Saibara; A Nishioka; Y Fujiwara; M Fukumoto; T Inomata; H Enzan; S Onishi; S Yoshida
Journal:  Oncol Rep       Date:  2000 Nov-Dec       Impact factor: 3.906

8.  Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men.

Authors:  Liesbeth Vandenput; Dan Mellström; Mattias Lorentzon; Charlotte Swanson; Magnus K Karlsson; John Brandberg; Lars Lönn; Eric Orwoll; Ulf Smith; Fernand Labrie; Osten Ljunggren; Asa Tivesten; Claes Ohlsson
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

9.  Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse.

Authors:  Kylie N Hewitt; Kyriakos Pratis; Margaret E E Jones; Evan R Simpson
Journal:  Endocrinology       Date:  2003-12-18       Impact factor: 4.736

10.  Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats.

Authors:  Yanjun Mu; Ruiping She; Hua Zhang; Bing Dong; Chengfei Huang; Wei Lin; Defa Li; Xiangdong Li
Journal:  Hepatol Res       Date:  2009-04-21       Impact factor: 4.288

View more
  43 in total

1.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.

Authors:  Zhen-Ya Lu; Zhou Shao; Ya-Li Li; Muhuyati Wulasihan; Xin-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

2.  Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer.

Authors:  Koji Matsuo; Marc R Gualtieri; Sigita S Cahoon; Carrie E Jung; Richard J Paulson; Donna Shoupe; Laila I Muderspach; Akihiko Wakatsuki; Jason D Wright; Lynda D Roman
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

3.  Genetic and hormonal control of hepatic steatosis in female and male mice.

Authors:  Frode Norheim; Simon T Hui; Emre Kulahcioglu; Margarete Mehrabian; Rita M Cantor; Calvin Pan; Brian W Parks; Aldons J Lusis
Journal:  J Lipid Res       Date:  2016-11-03       Impact factor: 5.922

Review 4.  Genetic Basis for Sex Differences in Obesity and Lipid Metabolism.

Authors:  Jenny C Link; Karen Reue
Journal:  Annu Rev Nutr       Date:  2017-06-19       Impact factor: 11.848

Review 5.  Role of Estrogens in the Regulation of Liver Lipid Metabolism.

Authors:  Brian T Palmisano; Lin Zhu; John M Stafford
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

6.  Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress.

Authors:  Yue Jia; Jennifer K Yee; Christina Wang; Liana Nikolaenko; Maruja Diaz-Arjonilla; Joshua N Cohen; Samuel W French; Peter Y Liu; YanHe Lue; Wai-Nang P Lee; Ronald S Swerdloff
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-09-19       Impact factor: 4.310

7.  Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Authors:  L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

8.  Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.

Authors:  Nima Motamed; Masoudreza Sohrabi; Hossein Ajdarkosh; Gholamreza Hemmasi; Mansooreh Maadi; Fatemeh Sima Sayeedian; Reza Pirzad; Khadijeh Abedi; Sivil Aghapour; Mojtaba Fallahnezhad; Farhad Zamani
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 9.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

10.  Nuclear Factor Erythroid 2-Related Factor 2 Deficiency Results in Amplification of the Liver Fat-Lowering Effect of Estrogen.

Authors:  Wenjuan Rui; Yuhong Zou; Joonyong Lee; Shashank Manohar Nambiar; Jingmei Lin; Linjie Zhang; Yan Yang; Guoli Dai
Journal:  J Pharmacol Exp Ther       Date:  2016-05-09       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.